ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
6066 articles about ACCESSWIRE
-
International Stem Cell Corporation Announces Successful Completion of Its Phase 1 Clinical Trial in Parkinson's Disease
6/30/2021
International Stem Cell Corporation announced today successful completion of its dose escalating phase 1 clinical trial.
-
Medifirst Solutions Appoints New CEO
6/30/2021
MEDIFIRST SOLUTIONS, INC. is pleased to announce naming Thomas Griffin as the Company's CEO. In the last 25 years, Mr. Griffin has been a global entrepreneur with proven success, a seasoned advisor and investor; a well-respected aviation, finance and business development executive.
-
Angle PLC Announces Result of AGM
6/30/2021
ANGLE plc, a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier , all resolutions were duly passed.
-
ReShape Lifesciences Completes $46 Million Capital Raise With Key Institutional Shareholders
6/30/2021
ReShape Lifesciences Inc., a global physician-led weight-loss and metabolic health solutions company, provided additional information about its previously announced warrant exercise agreement with existing accredited investors for approximately $46 million in gross proceeds.
-
Oakland Family Dental Now Utilizes Innovative i-CAT Technology as Part of their Dental Implant Services
6/30/2021
Oakland Family Dental is pleased to announce that the facility is using new state-of-the-art technology during dental implant treatments to create stunning smiles, change people's lives and improve their dental experience.
-
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
6/30/2021
CureVac N.V. today announced the appointment of Dr. Malte Greune as Chief Operating Officer (COO) effective July 1, 2021.
-
Viewpoint Molecular Targeting(R) Appoints Ewa Matczak MD, as Chief Medical Officer
6/30/2021
Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, announced the appointment of Ewa Matczak MD to the company as Chief Medical Officer.
-
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
6/30/2021
Oncology Pharma Inc. is developing a program to establish the use of its license utilizing NR2F6 agonists and antagonists coupled with the proprietary drug delivery systems in the treatment of various disorders including human pancreatic cancer and colon cancer.
-
EMulate Therapeutics to Participate in Access to Giving Virtual Investor Conference July 13th - 15th, 2021
6/30/2021
EMulate Therapeutics Inc., a clinical-stage therapeutic device company, announced today that management will participate in an Access to Giving Virtual Investor Conference July 13th - 15th, 2021.
-
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
6/29/2021
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the Phase 3 ORCA-2 trial of cytisinicline has reached its enrollment target of 750 adult smokers.
-
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR
6/29/2021
RELIEF THERAPEUTICS Holding AG announced that it has signed and closed the definitive agreement to acquire all outstanding shares of APR Applied Pharma Research S.A., a privately held Swiss pharmaceutical company with over 25 years' experience in identifying, developing and commercializing known molecules engineered with drug delivery systems in niche and rare diseases on a global basis.
-
StageZero Life Sciences' Annual and Special Meeting Update Presentation Will Be Available Post Meeting
6/29/2021
StageZero Life Sciences announced that it will post its Annual and Special Meeting Update Presentation on the Company website on Wednesday, June 30, 2021 at 4:00 p.m. ET.
-
Lexaria Announces 2021 Annual Meeting Results
6/29/2021
Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the results of the 2021 Annual Meeting.
-
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
6/29/2021
Aptevo Therapeutics Inc. today announced that the company has been added to the Russell Microcap Index at the conclusion of the 2021 annual reconstitution.
-
Patients Choice Laboratories Launches PCR Covid-19 Test Plus Variants
6/29/2021
Patients Choice Laboratories, a leading life sciences company, is proud to offer its PCR SARS-CoV-2 Test including 9 coronavirus variants. COVID-19 variants are now being considered by the CDC as a serious concern.
-
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering’s Lead Intratumoral Immunotherapy Candidate, MIE-101
6/29/2021
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company focused on immunotherapies to treat and prevent cancer and infectious diseases through innate and adaptive immune activation, announced a new preclinical publication available online in the journal Biomaterials that further expand the understanding of the antitumor potency and mechanism of action of the Company's lead immuno-oncology candidate, MIE-101, a novel Toll-like receptor tri-agonist.
-
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
6/28/2021
Aytu BioPharma, Inc. announced today that data from the first in-human, open label, clinical trial studying the safety and effectiveness of ultraviolet A (UVA) light endotracheal catheter therapy was published online on June 26, 2021 in the peer-reviewed journal Advances In Therapy.
-
Avinger Announces Key Opinion Leader Presentations at Vascular Conferences in Germany
6/28/2021
Avinger, Inc. today announced key opinion leader (KOL) presentations featuring the company's Lumivascular technology at two important vascular conferences held in Germany.
-
Celcuity Announces Pricing of Follow-on Offering
6/28/2021
Celcuity Inc., a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, announced the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $25.00 per share.
-
9 Meters Added to Russell 2000(R) and 3000(R) Indexes
6/28/2021
9 Meters Biopharma, Inc. announced today it has joined the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at the conclusion of the Russell U.S. Indexes annual reconstitution.